$ABBV — ADD 📊

$ABBV — ADD 📊 AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. 🎯 Q1 FY26 | Rev $15B | EPS $2.65 vs $2.67 🔴 | Margin 26.6% 💡 Consensus expected $2.67 adjusted EPS, and the miss reinforced patent-cliff fears, but underlying revenue growth of 12.4% and operating income expansion show momentum is stronger than priced. 📉 Reward/Risk: 2.2:1 🏢 Business Quality: 7/10 - Diversified immunology/oncology portfolio with high margins (operating margin 26.6%), strong pipeline (R&D 16.5% of revenue), and durable cash flows, but elevated debt ($64.5B) and ongoing Humira erosion weigh. 📊 Valuation: fair — 21x forward P/E (annualized adj. Also in play: $JNJ $PFE $MRK $LLY $BMY $TMO

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.